Sustained virologic response achieved after curative treatment of hepatitis C virus‐related hepatocellular carcinoma as an independent prognostic factor
- 13 February 2015
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 30 (7) , 1197-1204
Abstract
Background and Aim: Whether an antiviral interferon (IFN)‐based therapy (IBT) after curative treatment of hepatocellular carcinoma (HCC) improves the prognosis in patients with hepatitis C virus (HCV)‐related HCC remains to be elucidated.Methods: A total of 178 patients within the Milan criteria underwent curative treatment for HCV‐related HCC. Both the time to beyond the Milan criteria (TTBMC) and overall survival (OS) were compared between the sustained virologic response (SVR) (IFN with SVR, n = 22), non‐SVR (IFN without SVR, n = 19), and non‐IBT (control, n = 82) groups using propensity score matching analysis. Prognostic factors to predict survival were also determined by the Cox proportional‐hazards model.Results: TTBMC in the IFN with SVR group was significantly longer than those in the control and IFN without SVR groups (P < 0.001 and P = 0.006, respectively), although no significant difference existed between the IFN without SVR and control groups. Similarly, OS of the IFN with SVR group was significantly longer than that of the control and IFN without SVR groups (P < 0.001 and P = 0.029, respectively), although no significant difference existed between the IFN without SVR and control groups. The Cox proportional‐hazards model identified SVR as an independent prognostic factor in these patients. The IFN with SVR group showed a 0.096‐fold decrease in mortality risk compared with the control group (95% confidence intervals = 0.023–0.405; P = 0.001).Conclusion: Elimination of HCV after curative treatment of patients with HCC within the Milan criteria inhibits recurrence and contributes to a preferential prognosis.Keywords
This publication has 43 references indexed in Scilit:
- Effect and Safety of Interferon for Hepatocellular Carcinoma: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- A meta-analysis and systematic review: adjuvant interferon therapy for patients with viral hepatitis-related hepatocellular carcinomaWorld Journal of Surgical Oncology, 2013
- Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic FactorsAmerican Journal of Gastroenterology, 2012
- Management of Hepatocellular Carcinoma: An Update ΔσHepatology, 2011
- Effect of pegylated interferon therapy on intrahepatic recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinomaInternational Journal of Clinical Oncology, 2010
- Hepatitis C Virus Seromarkers and Subsequent Risk of Hepatocellular Carcinoma: Long-Term Predictors From a Community-Based Cohort StudyJournal of Clinical Oncology, 2010
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinomaHepatology International, 2010
- Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysisJournal of Hepatology, 2009
- Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosisHepatology, 2006